Mitoguazone
Chemical compound
- L01XX16 (WHO)
- (2E,2'E)-2,2'-(1E,2E)-propane-1,2-diylidenedihydrazinecarboximidamide
- 459-86-9
Y
- 5351154
- 4508218
N
- OD5Q0L447W
- D07258
Y
- CHEBI:43996
N
- DTXSID70861943
![Edit this at Wikidata](http://upload.wikimedia.org/wikipedia/en/thumb/8/8a/OOjs_UI_icon_edit-ltr-progressive.svg/10px-OOjs_UI_icon_edit-ltr-progressive.svg.png)
- Interactive image
- C\C(\C=N\NC(N)=N)=N/NC(N)=N
InChI
- InChI=1S/C5H12N8/c1-3(11-13-5(8)9)2-10-12-4(6)7/h2H,1H3,(H4,6,7,12)(H4,8,9,13)/b10-2+,11-3+
N
- Key:PKDBCJSWQUOKDO-UHFFFAOYSA-M
N
![☒](http://upload.wikimedia.org/wikipedia/commons/thumb/a/a2/X_mark.svg/7px-X_mark.svg.png)
![check](http://upload.wikimedia.org/wikipedia/en/thumb/f/fb/Yes_check.svg/7px-Yes_check.svg.png)
Mitoguazone (also known as methylglyoxal bis(guanylhydrazone) or MGBG) is a drug used in chemotherapy.[1]
References
- ^ Hoffmann H, Gutsche W, Amlacher R, Schulze W, Werner W, Lenk H, Wohlrab W, Haupt E (1989). "[Mitoguazone (methylglyoxal bis(guanylhydrazone))--its status and prospects]". Archiv für Geschwulstforschung (in German). 59 (2): 135–48. PMID 2655552.
- v
- t
- e
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
(M phase)
Block microtubule assembly | |
---|---|
Block microtubule disassembly |
inhibitor
DNA precursors/ antimetabolites (S phase) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Topoisomerase inhibitors (S phase) |
| ||||||||
Crosslinking of DNA (CCNS) |
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
![]() | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e